Terms: = Breast cancer AND HSP90AA1, ENSG00000080824, 3320, P07900, LAP2, HSPN, HSPCAL4, HSPCAL1, HSPCA, HSPC1, HSP90N, HSP90A, Hsp90, Hsp89, HSP86, FLJ31884 AND Clinical Outcome
7 results:
1. hsp90 N-terminal inhibitors target oncoprotein MORC2 for autophagic degradation and suppress MORC2-driven breast cancer progression.
Yang F; Sun R; Hou Z; Zhang FL; Xiao Y; Yang YS; Yang SY; Xie YF; Liu YY; Luo C; Liu GY; Shao ZM; Li DQ
Clin Transl Med; 2022 May; 12(5):e825. PubMed ID: 35522895
[TBL] [Abstract] [Full Text] [Related]
2. Investigation of the role of quercetin as a heat shock protein inhibitor on apoptosis in human breast cancer cells.
Kıyga E; Şengelen A; Adıgüzel Z; Önay Uçar E
Mol Biol Rep; 2020 Jul; 47(7):4957-4967. PubMed ID: 32638319
[TBL] [Abstract] [Full Text] [Related]
3. Heat shock proteins create a signature to predict the clinical outcome in breast cancer.
Klimczak M; Biecek P; Zylicz A; Zylicz M
Sci Rep; 2019 May; 9(1):7507. PubMed ID: 31101846
[TBL] [Abstract] [Full Text] [Related]
4. The targeted inhibition of hsp90 by a synthetic small molecule, DPide offers an effective treatment strategy against TNBCs.
Oh YJ; Park SY; Seo YH
Oncol Rep; 2018 Apr; 39(4):1775-1782. PubMed ID: 29436674
[TBL] [Abstract] [Full Text] [Related]
5. Leptin as a mediator of tumor-stromal interactions promotes breast cancer stem cell activity.
Giordano C; Chemi F; Panza S; Barone I; Bonofiglio D; Lanzino M; Cordella A; Campana A; Hashim A; Rizza P; Leggio A; Győrffy B; Simões BM; Clarke RB; Weisz A; Catalano S; Andò S
Oncotarget; 2016 Jan; 7(2):1262-75. PubMed ID: 26556856
[TBL] [Abstract] [Full Text] [Related]
6. TRAP1 is involved in BRAF regulation and downstream attenuation of ERK phosphorylation and cell-cycle progression: a novel target for BRAF-mutated colorectal tumors.
Condelli V; Piscazzi A; Sisinni L; Matassa DS; Maddalena F; Lettini G; Simeon V; Palladino G; Amoroso MR; Trino S; Esposito F; Landriscina M
Cancer Res; 2014 Nov; 74(22):6693-704. PubMed ID: 25239454
[TBL] [Abstract] [Full Text] [Related]
7. Medulloblastoma sensitivity to 17-allylamino-17-demethoxygeldanamycin requires MEK/ERKM.
Calabrese C; Frank A; Maclean K; Gilbertson R
J Biol Chem; 2003 Jul; 278(27):24951-9. PubMed ID: 12709419
[TBL] [Abstract] [Full Text] [Related]
